🇺🇸 FDA
Patent

US 11931421

Muscle targeting complexes and formulations for treating myotonic dystrophy

granted A61KA61K2039/505A61K45/06

Quick answer

US patent 11931421 (Muscle targeting complexes and formulations for treating myotonic dystrophy) held by Dyne Therapeutics, Inc. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/505, A61K45/06, A61K47/545, A61K47/548